Stakeholders back Medicare Part D out-of-pocket cap, call for additional changes to lower patient costs

The biopharmaceutical industry, patient groups, PBMs and other stakeholders have endorsed proposals to cap out-of-pocket drug costs for Medicare Part D beneficiaries in comments submitted to the House Ways and Means and Energy and Commerce Committees.

The committees asked for comments in May on draft legislation that would cap out-of-pocket (OOP) costs at the Medicare Part D catastrophic threshold, which is $5,100 in 2019. The legislation would phase-in

Read the full 683 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers